At Dyno, we welcome the opportunity to partner with leaders in gene therapy, leveraging its CapsidMap™ platform to research and develop AAV gene therapies incorporating Dyno’s proprietary capsids with improved tissue targeting, immune evasion, packaging size and manufacturability.

Dyno is continually building out its suite of proprietary gene therapy capsids which are available for licensing for gene therapy applications across a range of disease areas and indications.

To learn more about partnering and licensing with Dyno, please contact bd@dynotx.com.